Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion

•The ATHENA-HF clinical trial did not find additional decongestive benefit of spironolactone 100 mg/day for 96 hours in acute heart failure.•We performed a post hoc analysis of whether this spironolactone dosage had any pharmacodynamic effects.•We found that increased spironolactone dosing limited p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiac failure 2024-11, Vol.30 (11), p.1522-1526
Hauptverfasser:	NATOV, PETER S., IVEY-MIRANDA, JUAN B., COX, ZACHARY L., RAO, VEENA S., BUTLER, JAVED, KONSTAM, MARVIN A., KIERNAN, MICHAEL S., KAPUR, NAVIN K., TESTANI, JEFFREY M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Acute heart failure Aged congestion diuretics Diuretics - administration & dosage Diuretics - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Female Heart Failure - drug therapy Heart Failure - physiopathology Homeostasis - drug effects Homeostasis - physiology Humans Male Middle Aged mineralocorticoid receptor antagonist Mineralocorticoid Receptor Antagonists - administration & dosage Mineralocorticoid Receptor Antagonists - therapeutic use Potassium - blood potassium homeostasis spironolactone Spironolactone - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!